Eli Lilly and Company (NYSE:LLY) Shares Sold by Mediolanum International Funds Ltd

Mediolanum International Funds Ltd lessened its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 3.8% during the 3rd quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 115,877 shares of the company’s stock after selling 4,596 shares during the period. Eli Lilly and Company accounts for approximately 1.3% of Mediolanum International Funds Ltd’s investment portfolio, making the stock its 13th biggest holding. Mediolanum International Funds Ltd’s holdings in Eli Lilly and Company were worth $101,547,000 as of its most recent SEC filing.

Several other institutional investors have also recently added to or reduced their stakes in LLY. Lynx Investment Advisory purchased a new position in shares of Eli Lilly and Company during the second quarter worth about $32,000. LGT Financial Advisors LLC purchased a new position in Eli Lilly and Company during the 2nd quarter worth approximately $36,000. Redmont Wealth Advisors LLC acquired a new position in Eli Lilly and Company during the first quarter worth approximately $40,000. Morton Brown Family Wealth LLC increased its position in Eli Lilly and Company by 45.5% during the second quarter. Morton Brown Family Wealth LLC now owns 48 shares of the company’s stock worth $41,000 after buying an additional 15 shares during the period. Finally, Cedar Mountain Advisors LLC lifted its stake in Eli Lilly and Company by 53.3% in the third quarter. Cedar Mountain Advisors LLC now owns 46 shares of the company’s stock valued at $41,000 after buying an additional 16 shares during the last quarter. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Price Performance

LLY stock opened at $892.70 on Friday. The firm has a 50 day moving average of $919.74 and a 200-day moving average of $862.48. The company has a market cap of $848.45 billion, a price-to-earnings ratio of 109.94, a PEG ratio of 3.24 and a beta of 0.42. The company has a current ratio of 1.11, a quick ratio of 0.87 and a debt-to-equity ratio of 1.74. Eli Lilly and Company has a 12-month low of $547.61 and a 12-month high of $972.53.

Eli Lilly and Company (NYSE:LLY) last released its quarterly earnings data on Thursday, August 8th. The company reported $3.92 earnings per share for the quarter, beating the consensus estimate of $2.64 by $1.28. The firm had revenue of $11.30 billion during the quarter, compared to the consensus estimate of $9.83 billion. Eli Lilly and Company had a return on equity of 67.52% and a net margin of 18.86%. As a group, equities analysts expect that Eli Lilly and Company will post 14.05 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Truist Financial lifted their target price on shares of Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the company a “buy” rating in a report on Thursday, October 10th. Berenberg Bank upped their target price on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a report on Wednesday, August 14th. Bank of America raised their price target on Eli Lilly and Company from $1,000.00 to $1,125.00 and gave the stock a “buy” rating in a report on Friday, August 9th. Evercore ISI raised Eli Lilly and Company to a “hold” rating in a research note on Thursday, September 5th. Finally, Deutsche Bank Aktiengesellschaft reiterated a “buy” rating and issued a $1,025.00 target price on shares of Eli Lilly and Company in a research note on Thursday, October 3rd. Three research analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $1,013.41.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.